← Back to headlines
Guggenheim Initiates Tyra Biosciences with Buy Rating
Guggenheim has initiated coverage of Tyra Biosciences, Inc. (TYRA) with a 'Buy' rating, citing the strength of its lead drug, Dabogratinib.
24 Apr, 13:42 — 24 Apr, 13:42
Sources
Showing 1 of 1 sources
